EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer

Alexander B Olawaiye iD, Jae-Weon Kim iD, Andrea Bagameri iD, Erin Bishop iD, Anita Chudecka-Głaz iD, Alix Devaux iD, Laurence Gladieff iD, Mary E Gordinier iD, Jacob Korach iD, Michael E McCollum iD, Linda Mileshkin iD, Bradley J Monk iD und 8 weitere

Journal of Gynecologic Oncology · 2024 · 35 (4)

DOI: 10.3802/jgo.2024.35.e111 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Alexander B Olawaiye und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh School of Medicine and Magee-Womens Hospital, Gynecologic Oncology Group, Pittsburgh, PA, USA. olawaiyea@upmc.edu. Hauptthemen laut MEDLINE: Albumins, Antineoplastic Combined Chemotherapy Protocols, Drug Resistance, Neoplasm, Ovarian Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Corcept Therapeutics, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ovarian cancer has the highest mortality among gynecologic cancers, primarily because it typically is diagnosed at a late stage and because of the development of chemoresistance in recurrent disease. Improving outcomes in women with platinum-resistant ovarian cancer is a substantial unmet need. Activation of the glucocorticoid receptor (GR) by cortisol has been shown to suppress the apoptotic pathways used by cytotoxic agents, limiting their efficacy. Selective GR modulation may be able to counteract cortisol's antiapoptotic effects, enhancing chemotherapy's efficacy. A previous phase 2 study has shown that adding intermittently dosed relacorilant, a selective GR modulator, to nab-paclitaxel improved outcomes, including progression-free survival (PFS) and overall survival (OS), with minimal added toxicity, in women with recurrent platinum-resistant ovarian cancer. The ROSELLA study aims to confirm and expand on these findings in a larger population. METHODS: ROSELLA is a phase 3, randomized, 2-arm, open-label, global multicenter study in women with recurrent, platinum-resistant, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer. Eligible participants have received 1 to 3 lines of prior systemic anticancer therapy, including ≥1 prior line of platinum therapy and prior treatment with bevacizumab, with documented progressive disease or intolerance to the most recent therapy. There is no biomarker-based requirement for participant selection. Participants are randomized 1:1 to receive intermittently dosed relacorilant in combination with nab-paclitaxel or nab-paclitaxel monotherapy. The study's primary efficacy endpoint is PFS as assessed by blinded independent central review. Secondary efficacy endpoints include OS, investigator-assessed PFS, objective response rate, best overall response, duration of response, clinical benefit rate at 24 weeks, and cancer antigen 125 response. The study is also evaluating safety and patient-reported outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05257408; European Union Drug Regulating Authorities Clinical Trials Database Identifier: 2022-000662-18.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbuminsAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmOvarian NeoplasmsPaclitaxelFemaleHumansCarcinoma, Ovarian EpithelialClinical Trials, Phase III as TopicMulticenter Studies as TopicNeoplasm Recurrence, LocalProgression-Free SurvivalRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Glucocorticoid ReceptorNab-paclitaxelNeoplasm Drug ResistanceOvarian NeoplasmsRelacorilant

Substanzen

130-nm albumin-bound paclitaxelAlbuminsPaclitaxel

Autor:innen und Institutionen

  • University of Pittsburgh School of Medicine and Magee-Womens Hospital, Gynecologic Oncology Group, Pittsburgh, PA, USA. olawaiyea@upmc.edu.
  • Department of Obstetrics and Gynecology, Seoul National University, Seoul, Korea.
  • National Institute of Oncology, Budapest, Hungary.
  • Medical College of Wisconsin, Gynecologic Oncology Group, Milwaukee, WI, USA.
  • Pomeranian Medical University, Polish Gynecologic Oncology Group, Szczecin, Poland.
  • Oncology Department of Grand Hôpital de Charleroi, Charleroi, Belgium.

ORCID-Profile: Alexander B Olawaiye, Jae-Weon Kim, Andrea Bagameri, Erin Bishop, Anita Chudecka-Głaz, Alix Devaux, Laurence Gladieff, Mary E Gordinier, Jacob Korach, Michael E McCollum, Linda Mileshkin, Bradley J Monk, Shibani Nicum, Angélica Nogueira-Rodrigues, Ana Oaknin, David M O'Malley, Mauro Orlando, Lyndah Dreiling, Iulia C Tudor, Domenica Lorusso

Förderung

  • Corcept Therapeutics, Inc.

Zitieren

APA

Olawaiye, A. B., Kim, J. W., Bagameri, A., Bishop, E., Chudecka-Głaz, A., Devaux, A., Gladieff, L., Gordinier, M. E., Korach, J., McCollum, M. E., Mileshkin, L., Monk, B. J., Nicum, S., Nogueira-Rodrigues, A., Oaknin, A., O'Malley, D. M., Orlando, M., Dreiling, L., Tudor, I. C., & Lorusso, D. (2024). Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer. Journal of Gynecologic Oncology, 35(4). https://doi.org/10.3802/jgo.2024.35.e111

Vancouver

Olawaiye AB, Kim JW, Bagameri A, Bishop E, Chudecka-Głaz A, Devaux A, et al. Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer. Journal of Gynecologic Oncology. 2024;35(4). doi:10.3802/jgo.2024.35.e111

BibTeX
@article{Olawaiye2024,
  author = {Olawaiye, Alexander B and Kim, Jae-Weon and Bagameri, Andrea and Bishop, Erin and Chudecka-Głaz, Anita and Devaux, Alix and Gladieff, Laurence and Gordinier, Mary E and Korach, Jacob and McCollum, Michael E and Mileshkin, Linda and Monk, Bradley J and Nicum, Shibani and Nogueira-Rodrigues, Angélica and Oaknin, Ana and O'Malley, David M and Orlando, Mauro and Dreiling, Lyndah and Tudor, Iulia C and Lorusso, Domenica},
  title = {Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  volume = {35},
  number = {4},
  doi = {10.3802/jgo.2024.35.e111}
}
Kostenlos starten →